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Abstract
Oral anticoagulants (OACs) antagonizing vitamin K - fundamentally sodium warfarin and acenocoumarol - are wi-
dely used for preventing arterial thromboembolism in patients with atrial fibrillation and/or heart valve prostheses, 
and for the treatment and prevention of deep venous thrombosis and pulmonary embolism.
The handling of these drugs requires correct monitorization and dose adjustment to obtain the desired therapeutic 
effect while minimizing the adverse effects associated both with excessive anticoagulation (which leads to bleeding) 
and with insufficient antithrombotic action (which can produce thrombosis). This is particularly important when 
patients must be subjected to surgical procedures such as tooth extractions. In this context, a number of management 
recommendations are available. 
The present study offers an update on the recommendations for the management of anticoagulated patients program-
med for tooth extractions. In recent years, most studies do not recommend reducing or interrupting anticoagulation, 
or replacing it with heparin, prior to tooth extraction - provided therapeutic international normalized ration (INR) 
levels are maintained, with emphasis on the application of local measures such as antifibrinolytic agents, for the 
control of hemostasia. 
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Introduction
The term oral anticoagulant (OAC) refers to oral vitamin 
K antagonists, including mainly sodium warfarin (the 
most widely used agent in Anglo-Saxon countries) and 
acenocoumarol (widely used in Spain). These drugs are 
widely prescribed for preventing arterial thromboembo-
lism in patients with atrial fibrillation and/or heart valve 
prostheses, and for the treatment and prevention of deep 
venous thrombosis and pulmonary embolism (1).
The handling of these drugs requires correct monitoriza-
tion and dose adjustment to obtain the desired therapeutic 
effect while minimizing the adverse effects associated both 
with excessive anticoagulation (which leads to bleeding) 
and with insufficient antithrombotic action (which can 
produce thrombosis)(1).
When such patients require surgery (e.g., tooth extrac-
tions), increased bleeding risk is postulated if  the OAC 
dose is not lowered. However, reducing the drug levels 
in turn can increase the risk of thromboembolism. Thus, 
a series of  management guidelines are needed in such 
situations.
The present study offers an update on OACs and on the 
recommendations for the management of anticoagulated 
patients programmed for tooth extractions, based on the 
results of clinical studies and expert opinions. 
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Oral anticoagulants
Anticoagulant drugs inhibit the plasma phase of blood 
clotting by either liver synthesis of coagulation factors 
(oral anticoagulants, OACs) or blocking the action of 
already formed factors (heparins). Thus, the term OAC 
refers to oral antagonists of vitamin K.
OACs can be derived from coumarin (4-hydroxycoumarin, 
sodium warfarin, phenprocoumon, acenocoumarol, di-
coumarol) or indandiones (indan-1,3-dione, anisindione, 
phenindione). The coumarin derivatives are the most 
widely used OACs, and in this context sodium warfarin 
(Coumadin®) is the most commonly used agent in Anglo-
Saxon countries, while acenocoumarol (Sintrom®) is the 
most widely used drug Spain. The indandiones are pre-
sently little used, due to their adverse effects - particularly 
hypersensitivity (1-3). 
OACs inhibit the enzyme vitamin K reductase, which 
converts vitamin K epoxide to its active form. The vitamin 
K-dependent blood coagulation factors (factor II, VII, IX, 
X and proteins C, S and Z) present a group of carboxyglu-
tamic acid residues (GLA residues) that allow binding of 
the factor (via ionic calcium bonds) to the carboxyl and 
hydroxyl radicals of  the membrane phospholipids of 
platelets and other cells - resulting in physiological blood 
coagulation. Supplementary carboxylation of glutamic 
acid requires the participation of vitamin K in its active 
form (hydroquinone) - the latter being degraded to epoxide 
during the process. By means of reductases, the liver cells 
regenerate this epoxide into the active form of the vitamin, 
thereby allowing another cycle of  formation of  active 
coagulation factors. This continuous recycling process 
explains why only small daily amounts of vitamin K are 
needed. OACs that are structurally similar to vitamin K 
competitively interfere with its regeneration process. In 
the absence of active vitamin K, proteins lacking GLA 
residues are synthesized, and such factors are unable to 
participate in blood coagulation (4,5).
The anticoagulant effect in turn depends on the half-life of 
the inhibited factors. In this sense, the half-lives of factors 
VII, IX, X and II are 6, 24, 40 and 60 hours, respectively. 
Blood coagulation factor VII is the first to be affected, 
prolonging prothrombin time (PT). Factors IX, X and 
II are posteriorly affected: factor IX prolongs activated 
partial thromboplastin time (aPTT), while factors X and 
II prolong both PT and aPTT (6). 
These are well tolerated drugs, with rapid absorption via 
the oral route. The peak plasma concentrations are reached 
one hour after administration, though the reduction in 
coagulation factors takes place 48-72 hours after dosing. 
The half-life of warfarin is 48-72 hours, versus 8-10 hours 
in the case of acenocoumarol. Thus, the effects of warfa-
rin are longer lasting in terms of both the induction and 
disappearance of therapeutic action.
Some patients are particularly sensitive to OACs, and the 
activity of these drugs moreover can be affected by a range 
of factors including individual patient response, diet, or 
the simultaneous administration of other commonly used 
drugs such as antibiotics, analgesics, or even herbal reme-
dies. As a result, regular monitorization is required, and 
such control must be more frequent when changes occur 
in any of the aforementioned aspects (3,5). 
OAC action is monitored on the basis of the effect of such 
drugs on prothrombin time (PT), i.e., the time required for 
the clotting of citrate-treated plasma, after adding calcium 
and thromboplastin. Thromboplastin is extracted from 
different tissues with different levels of sensitivity - a fact 
that complicates the comparison of PT test results. The 
PT results are usually reported as the ratio patient time / 
control time. The simple ratio is extremely variable, depen-
ding on the sensitivity of the reagent used - thus making it 
impossible to establish universally applicable therapeutic 
margins. For this reason, in 1978 the World Health Orga-
nization (WHO) recommended PT standardization, and 
in 1983 it introduced the INR (international normalized 
ratio), which is calculated by raising the simple ratio to 
the international sensitivity index (ISI) of the thrombo-
plastin used. Thus, INR = (patient time / control time) 
ISI. This is the formula used to standardize PT, allowing 
comparison regardless of the thromboplastin used by the 
different laboratories, and ensuring increased reliability in 
monitoring OAC treatment. At the same time, the diffe-
rent international societies established recommendations 
regarding the therapeutic anticoagulation levels to be 
maintained according to the existing patient pathology 
- the corresponding INR value ranging from 2 to 3.5 
(Table 1)(4,7). Thus, there is a strong correlation between 
Clinical pathology INR
- Prophylaxis – venous thromboembolism (high risk surgery)
- Prophylaxis – venous thromboembolism (hip surgery)
- Treatment of deep venous thrombosis or pulmonary embolism
- Prevention of systemic embolism in patients with atrial fibrillation, heart 
valve disease, bioprostheses, or acute myocardial infarction
- Valve prostheses, recurrent systemic embolism, recurrent myocardial 
infarction
2.0-3.0
2.0-3.0
2.0-3.0
2.0-3.0
2.5-3.5
Table 1. Therapeutic anticoagulation levels (2,3).
INR = international normalized ratio
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INR and bleeding risk - the latter increasing when INR 
>4. However, there are also other factors to be taken into 
account that may facilitate bleeding, such as the existing 
background disease (e.g., liver pathology, bone marrow 
alterations, anemia, malabsorption, kidney disease) and 
the administration of different drugs. There are both effect 
enhancing drugs - which generally act by displacing the 
coumarinic agent from the plasma albumin transporter to 
which it is bound - and effect reducing or inhibiting drugs 
that block the intestinal absorption of the coumarin drug 
or accelerate its metabolism. Following the introduction 
of a new drug, it is advisable to perform more frequent 
laboratory controls (4,5,8). The prophylactic antibiotic 
dose which some patients require before tooth extraction 
does not appear to affect the capacity to secure adequa-
te hemostasia. In contrast, longer antibiotic treatment 
exerts a greater effect, since it alters vitamin K absorption 
secondary to action upon the gastrointestinal flora, with 
an increase in bleeding risk (3).
The experts always recommend monitoring INR on the 
same day as tooth extraction (1-6).
Management of orally anticoagulated patients requi-
ring surgery
Due in part to the lack of randomized studies, a number of 
recommendations have been made for the management of 
anticoagulated patients programmed for surgery, in view 
of the need to lower the OAC regimen in order to prevent 
bleeding complications, while at the same time avoiding 
thromboembolic phenomena secondary to this reduction 
in INR to subtherapeutic values. 
The recommendations vary according to the bleeding 
risk of  the surgical intervention and the indication of 
anticoagulation therapy (i.e., the thromboembolic risk 
of the patient). Thus, for example, treatment to prevent 
venous thromboembolism is not the same as treatment for 
dealing with an acute thrombotic episode.
Although consensus is lacking, the expert groups do es-
tablish a series of recommendations:
- For patients at low risk of bleeding after the operation, 
anticoagulation can be maintained at the lower limit of 
the therapeutic range (INR = 2.0).
- For patients at high bleeding risk, anticoagulation should 
be maintained at subtherapeutic levels (INR = 1.5). Ac-
cordingly, acenocoumarol should be suspended 3-4 days 
before surgery (4-5 days in the case of warfarin). On day 
-3, low molecular weight heparin (LMWH) should be 
provided at therapeutic, medium or prophylactic doses, 
depending on whether the thrombotic risk of the patient 
is high, moderate or low, respectively. This is to be main-
tained until 12 hours before surgery, followed 12 hours 
after surgery be reintroduction of the original treatment, 
provided there is no bleeding (1,4-6).
Depending on the existing thromboembolic risk, the Ame-
rican Heart Association / American College of Cardiology 
Foundation Guide to Warfarin Therapy recommends 
different heparin management regimens:
- Patients with moderate thromboembolic risk: Adminis-
tration of prophylactic LMWH doses of 3000 U via the 
subcutaneous route (every 12 hours) prior to surgery until 
the INR values have been normalized, with the reintro-
duction of treatment 12 hours after surgery together with 
the OACs combined during 4-5 days, until the therapeutic 
anticoagulation levels of the patient have been reached. In 
the event of important bleeding risk after the operation, 
heparin or LMWH dosing is to be postponed 24 hours 
or more. 
- Patients with high thromboembolic risk: In these cases 
heparin dosing must be therapeutic rather than prophylac-
tic: 100 U LMWH every 12 hours via the subcutaneous 
route. Administration is to be interrupted 24 hours before 
surgery. If  the maintenance of patient anticoagulation is 
a critical consideration, then heparin can be administered 
in hospital at a dose of 1300 U/hour via intravenous infu-
sion, with suspension 5 hours before surgery. Heparin or 
LMWH can be resumed 12 hours after the intervention 
at prophylactic doses alone or in combination with OACs, 
until the INR value has been restored. 
- Patients with low thromboembolic risk: OAC can be 
suspended and resumed after the operation, with subcuta-
neous LMWH supplements every 12 hours, if  necessary.
In general, heparins are not reintroduced before 12 hours 
postsurgery, and dosing is postponed for longer periods 
in the case of evidence of bleeding (4).
Orally anticoagulated patients and extractions
However, the recommendations in the case of minor surgery 
- including tooth extraction - appear to be more unanimous. 
In effect, most sources recommend that OAC should not 
be interrupted, working within a therapeutic INR range of 
2-3 or 2.5-3.5, depending on the pathology involved (Table 
1)(1,4,9,10), in view of the low bleeding risk that does not 
justify increasing the risk of thromboembolism associated 
with OAC reduction or suspension. Recent randomized 
studies such as the work published by Sacco in 2007 (11) 
compare the complications between two groups of pa-
tients subjected to oral surgery: one with OAC reduction 
to subtherapeutic INR levels (INR = 1.8), and the other 
without OAC reduction and presenting therapeutic INR 
values, with postoperative local hemostatic measures. The 
conclusion is that there are no differences between the two 
groups warranting a reduction in OAC coverage. 
Not all authors coincide with this view, however, and there 
are protocols that advise interruption or reduction of OAC 
in the days prior to the intervention, in order to secure 
subtherapeutic INR levels (INR <2) in a short period of 
time before the operation. This measure is suggested to 
be safe in patients requiring dental extraction, preventing 
the development of bleeding episodes (12-14).
The different studies not only relate post-extraction blee-
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ding to the absolute INR values, but also to the general 
patient condition, the surgical technique employed, and 
the patient preparation and instructions provided (10,15). 
In this sense, bleeding reduction in these patients is facili-
tated by a lessening of tissue inflammation and irritation 
(oral hygiene, tartar removal, chlorhexidine rinses) before 
extraction, a careful surgical technique with thorough 
socket curettage to remove the inflammatory and granula-
tion tissue, followed by wound compression, suturing and 
compression with dressings impregnated with tranexamic 
acid or epsilon-aminocaproic acid (11,15). 
The placement of fibrin adhesives, oxidized cellulose and 
gelatin sponges in the tooth socket has also been suggested, 
to help clot formation before suturing (3,10,11).
Studies have been made of  the use of  antifibrinolytic 
agents (3,11), which favor local hemostasia by inhibiting 
fibrinolysis - such as tranexamic acid in the form of soc-
ket irrigating solutions and rinses in the days following 
tooth extraction. In 2003, Carter et al. (16) conducted a 
randomized study in patients under oral anticoagulation 
and subjected to extractions without modifying the OAC 
regimen, and applying two types of  hemostatic agents 
(4.8% tranexamic acid and autologous fibrin adhesive). 
The authors concluded that both approaches are effective 
and safe in controlling post-extraction bleeding. In this 
context, increased efficacy was obtained with socket irri-
gation using 10 ml of tranexamic acid immediately after 
extraction, with the placement of  absorbable oxidized 
cellulose impregnated with tranexamic acid in the socket, 
and reabsorbable suturing with tranexamic acid rinses 
(10 ml four times a day during 7 days). Autologous fibrin 
adhesive applied to the socket walls in turn was recom-
mended when the patient has difficulties performing rinses 
correctly. Posterior studies reported the same efficacy in 
controlling hemostasia by applying rinses for only two 
days (17). Tranexamic acid has no marketing license in 
the United Kingdom, and fibrin adhesives (Tissucol®) are 
not recommended by all authors, due to the risk of disease 
transmission - though such systems are subjected to viral 
inactivation processes - and their high cost (8).
Post-extraction bleeding is generally controlled by local 
measures such as socket curettage, suturing, and local 
compression, thanks to easy access to the bleeding zone. 
When such measures prove insufficient, and the anticoa-
gulation effect must be suppressed, this can be done by 
administering vitamin K. In this sense, intravenous ad-
ministration elicits faster effects than the oral route - the 
recommended dose being 5-10 mg. The use of concentrates 
of prothrombin complex or fresh frozen plasma is reserved 
for cases of important bleeding. Based on the evidence that 
the benefit of preventing thromboembolism outweighs the 
risk of bleeding, the recommendations of the published 
clinical studies and the expert opinions are to keep the 
OAC dose unchanged, working with therapeutic INR 
levels, and adopting local hemostatic measures - with the 
use of antifibrinolytic agents such as tranexamic acid, in 
dental extractions. More invasive oral surgery with an 
increased bleeding risk may constitute an exception to 
these guidelines, requiring due evaluation in coordination 
with the hematologist (3,5).
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